Ocular Therapeutix (OCUL) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

OCUL Ocular Therapeutix

Watchlist

6.940
+0.170+2.51%

Close Feb 26 16:00 ET

6.310
-0.630-9.08%

Pre 04:32 ET

1.09BMarket Cap-5.83P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Top Executives Unload Thousands of Ocular Therapeutix Shares!
TipRanks21:03 ET
Earnings Preview: OCUL to Report Financial Results Pre-market on March 03
Moomoo NewsFeb 25 20:00 ET
Ocular Therapeutix to Present at Two Investor Conferences in March
GlobeNewswireFeb 25 07:00 ET
Ocular Therapeutix to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025
GlobeNewswireFeb 24 07:00 ET
Ocular Therapeutix Approves New CEO Compensation Package
TipRanksFeb 14 07:57 ET
Raymond James Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $19
Moomoo NewsFeb 5 17:31 ET · Ratings

Comments

Trytosaveabit

Aug 7, 2024 06:11

Update

$Ocular Therapeutix (OCUL.US)$ Ocular Therapeutix Has Received FDA Written Response That Phase 3 Sol-r Trial Is Appropriate For Use As The Company's Second Adequate And Well Controlled Study Of Axpaxli (Axitinib Intravitreal Implant, Also Known As OTX-TKI) For Wet Age-related Macular Degeneration